Patient Reported Outcomes for GRAIL’s Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it…